Surrogate Endpoints Envisioned For Heart Failure Diagnostic Trials
This article was originally published in The Gray Sheet
Executive Summary
Medical device firms attempting to validate surrogate endpoints in clinical trials may benefit from early-stage collaborations with pharmaceutical companies, according to CDRH Cardiovascular Devices Branch Chief Bram Zuckerman, MD
You may also be interested in...
Heart Failure Device Trial Investigators Search For Metrics Beyond Mortality
FDA should collaborate with the Heart Failure Society of America to draft guidelines for composite and surrogate endpoints in heart failure device trials, HFSA workshop participants urged April 1
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.